- Home
- SERV vs ABUS Comparison
SERV vs ABUS Comparison
Compare SERV & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- ABUS
- Stock Information
- Founded
- SERV 2017
- ABUS 2005
- Country
- SERV United States
- ABUS United States
- Employees
- SERV N/A
- ABUS N/A
- Industry
- SERV Industrial Specialties
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- ABUS Health Care
- Exchange
- SERV Nasdaq
- ABUS Nasdaq
- Market Cap
- SERV 609.5M
- ABUS 711.2M
- IPO Year
- SERV N/A
- ABUS N/A
- Fundamental
- Price
- SERV $13.75
- ABUS $4.18
- Analyst Decision
- SERV Buy
- ABUS Strong Buy
- Analyst Count
- SERV 5
- ABUS 2
- Target Price
- SERV $17.75
- ABUS $5.00
- AVG Volume (30 Days)
- SERV 12.1M
- ABUS 1.3M
- Earning Date
- SERV 11-06-2025
- ABUS 11-05-2025
- Dividend Yield
- SERV N/A
- ABUS N/A
- EPS Growth
- SERV N/A
- ABUS N/A
- EPS
- SERV N/A
- ABUS N/A
- Revenue
- SERV $1,479,483.00
- ABUS $15,416,000.00
- Revenue This Year
- SERV $133.00
- ABUS $138.02
- Revenue Next Year
- SERV $795.71
- ABUS N/A
- P/E Ratio
- SERV N/A
- ABUS N/A
- Revenue Growth
- SERV N/A
- ABUS 53.23
- 52 Week Low
- SERV $4.66
- ABUS $2.71
- 52 Week High
- SERV $24.35
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- SERV 60.50
- ABUS 51.25
- Support Level
- SERV $11.23
- ABUS $4.29
- Resistance Level
- SERV $15.65
- ABUS $4.54
- Average True Range (ATR)
- SERV 1.11
- ABUS 0.17
- MACD
- SERV 0.16
- ABUS -0.05
- Stochastic Oscillator
- SERV 58.46
- ABUS 25.78
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.